MitrAssist
Date | Investors | Amount | Round |
---|---|---|---|
N/A | $1.0m | Angel | |
* | $30.0m | Late VC | |
$50.0m Valuation: $300m | Series B | ||
* | $100m | Series C | |
Total Funding | $181m |
Related Content
Recent News about MitrAssist
EditMitrAssist is a medical device company specializing in minimally invasive treatments for Mitral Regurgitation (MR), a condition affecting the heart's mitral valve. The company targets patients who are unable to undergo risky open-heart surgery, providing a safer alternative with its innovative mitral valve implant. This implant works in harmony with the natural mitral valve, preserving its functionality and adapting to various anatomical shapes. MitrAssist operates in the healthcare market, specifically focusing on cardiology and medical devices. The business model revolves around the development, manufacturing, and distribution of its proprietary mitral valve implants to hospitals and healthcare providers. Revenue is generated through the sale of these implants and associated medical services. The company's solution is designed to be long-lasting, significantly reducing both the procedure and recovery times for patients, making it suitable for individuals of all ages.
Keywords: Mitral Regurgitation, minimally invasive, heart valve, cardiology, medical device, healthcare, patient safety, implant, recovery time, innovative treatment.